High-Sensitivity Troponin I Levels and Coronary Artery Disease Severity, Progression, and Long-Term Outcomes.

MedStar author(s):
Citation: Journal of the American Heart Association. 7(5), 2018 02 21.PMID: 29467150Institution: MedStar Health Research InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, N.I.H., Extramural | Research Support, Non-U.S. Gov'tSubject headings: *Coronary Artery Disease/bl [Blood] | *Coronary Stenosis/bl [Blood] | *Troponin I/bl [Blood] | Aged | Biomarkers/bl [Blood] | Cause of Death | Coronary Angiography | Coronary Artery Disease/dg [Diagnostic Imaging] | Coronary Artery Disease/mo [Mortality] | Coronary Stenosis/dg [Diagnostic Imaging] | Coronary Stenosis/mo [Mortality] | Disease Progression | Female | Georgia/ep [Epidemiology] | Humans | Incidence | Male | Middle Aged | Predictive Value of Tests | Prognosis | Retrospective Studies | Risk Assessment | Risk Factors | Severity of Illness Index | Time FactorsYear: 2018ISSN:
  • 2047-9980
Name of journal: Journal of the American Heart AssociationAbstract: BACKGROUND: The associations between high-sensitivity troponin I (hsTnI) levels and coronary artery disease (CAD) severity and progression remain unclear. We investigated whether there is an association between hsTnI and angiographic severity and progression of CAD and whether the predictive value of hsTnI level for incident cardiovascular outcomes is independent of CAD severity.CONCLUSIONS: Higher hsTnI levels are associated with the underlying burden of coronary atherosclerosis, more rapid progression of CAD, and higher risk of all-cause mortality and incident cardiovascular events. Whether more aggressive treatment aimed at reducing hsTnI levels can modulate disease progression requires further investigation.Copyright (c) 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.METHODS AND RESULTS: In 3087 patients (aged 63+/-12 years, 64% men) undergoing cardiac catheterization without evidence of acute myocardial infarction, the severity of CAD was calculated by the number of major coronary arteries with >=50% stenosis and the Gensini score. CAD progression was assessed in a subset of 717 patients who had undergone >=2 coronary angiograms >3 months before enrollment. Patients were followed up for incident all-cause mortality and incident cardiovascular events. Of the total population, 11% had normal angiograms, 23% had nonobstructive CAD, 20% had 1-vessel CAD, 20% had 2-vessel CAD, and 26% had 3-vessel CAD. After adjusting for age, sex, race, body mass index, smoking, hypertension, diabetes mellitus history, and renal function, hsTnI levels were independently associated with the severity of CAD measured by the Gensini score (log 2 s=0.31; 95% confidence interval, 0.18-0.44; P<0.001) and with CAD progression (log 2 s=0.36; 95% confidence interval, 0.14-0.58; P=0.001). hsTnI level was also a significant predictor of incident death, cardiovascular death, myocardial infarction, revascularization, and cardiac hospitalizations, independent of the aforementioned covariates and CAD severity.All authors: Abdelhadi N, Alkhoder A, Beshiri A, Choudhary F, Epstein SE, Gafeer MM, Ghasemzadeh N, Hammadah M, Hayek SS, Kelli HM, Kim J, Ko YA, Murtagh G, O'Neal WT, Patel K, Quyyumi AA, Samman Tahhan A, Sandesara P, Shaw L, Sperling L, Topel M, Vaccarino V, Wilson PFiscal year: FY2018Digital Object Identifier: Date added to catalog: 2018-02-28
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 29467150 Available 29467150

BACKGROUND: The associations between high-sensitivity troponin I (hsTnI) levels and coronary artery disease (CAD) severity and progression remain unclear. We investigated whether there is an association between hsTnI and angiographic severity and progression of CAD and whether the predictive value of hsTnI level for incident cardiovascular outcomes is independent of CAD severity.

CONCLUSIONS: Higher hsTnI levels are associated with the underlying burden of coronary atherosclerosis, more rapid progression of CAD, and higher risk of all-cause mortality and incident cardiovascular events. Whether more aggressive treatment aimed at reducing hsTnI levels can modulate disease progression requires further investigation.

Copyright (c) 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

METHODS AND RESULTS: In 3087 patients (aged 63+/-12 years, 64% men) undergoing cardiac catheterization without evidence of acute myocardial infarction, the severity of CAD was calculated by the number of major coronary arteries with >=50% stenosis and the Gensini score. CAD progression was assessed in a subset of 717 patients who had undergone >=2 coronary angiograms >3 months before enrollment. Patients were followed up for incident all-cause mortality and incident cardiovascular events. Of the total population, 11% had normal angiograms, 23% had nonobstructive CAD, 20% had 1-vessel CAD, 20% had 2-vessel CAD, and 26% had 3-vessel CAD. After adjusting for age, sex, race, body mass index, smoking, hypertension, diabetes mellitus history, and renal function, hsTnI levels were independently associated with the severity of CAD measured by the Gensini score (log 2 s=0.31; 95% confidence interval, 0.18-0.44; P<0.001) and with CAD progression (log 2 s=0.36; 95% confidence interval, 0.14-0.58; P=0.001). hsTnI level was also a significant predictor of incident death, cardiovascular death, myocardial infarction, revascularization, and cardiac hospitalizations, independent of the aforementioned covariates and CAD severity.

English

Powered by Koha